Chicago has always been a hotbed for technological innovation and now the Windy City is getting involved with the medical field through a rising start-up known as Tempus. Tempus was co-founded by Eric Lefkofsky in 2015 with the goal of helping to revolutionize the way that customers and medical health professionals interact with and access important medical data. The company is now valued at north of $1 billion and this has allowed Tempus to earn the coveted Unicorn Status.
The goal of Tempus is to utilize data in a way that helps to streamline and maximize the effectiveness of cancer care in the modern medical world. Having seen how the system works up close, through a personal relationship, Lefkofsky came to the realization that there is a ton of room for improvement within the field. So, Tempus compiles data from multiple sources before porting it into an accessible database. This database is then utilized by patients, family members and healthcare professionals in order to track cancer care approaches and see which ones are most effective.
We are currently living in the data-driven age of technology and Lefkofsky’s approach as the co-founder of Tempus is serving as a unique opportunity to help change lives through data. Leaning on clinical data and molecular data, Tempus is quickly becoming vital in the search for trends among cancer care patients. Tempus relies not only on old data but it also ports data from patients that are currently undergoing treatment. The data collection system is advanced enough that it can utilize digital database and simple enough that it can be used to port in handwritten doctor notes into a searchable platform.
Right now, Tempus employs nearly 400 workers and their business forecast shows that the company will be adding nearly 30 new employees every single month from here on out. With success in their approach, Tempus has quickly captured the eye of several major investors. It was recently announced that Tempus had earned an additional $80 million in investments which pushes their 3-year-total to just north of $210 million. With this kind of early success, the sky appears to be the limit for Tempus.
A study shows that transplantation of one’s blood-forming stem cells after high-dose immunosuppressive may induce remission of multiple sclerosis. Multiple sclerosis (MS) is a condition in which an individual’s immune system attacks his or her central nervous system. The study was conducted over a period of about five years. It was published in the American Academy of Neurology journal.
From the research, 69 percent of the participants (patients) who underwent high-dose immunosuppressive therapy and autologous hematopoietic cell transplant treatment (HDIT/HCT) did not experience progression of disability, new brain lesions, and relapse of MS symptoms. In other studies, it has been found that MS drugs available in the market have limited success rate in treating the disease. The National Institute of Allergy and Infectious Diseases (NIAID) sponsored the study. The first results of the study were posted in December 2014.
According to Anthony S. Fauci, M.D., long-term treatment of MS even with the best medications in the market is less efficient than one-time treatment with HDIT/HCT. He also pointed out that MS varies from one person to another. Fauci added that the results of these studies support the need to conduct a large and randomized trial. He believes that this process will help produce reliable data that could be used to compare the success of HDIT/HCT treatments to standard MS care. MS symptoms include weakness, fatigue, motor and speech difficulties, and chronic pain. The most common type of MS is relapsing-remitting MS. This information was originally reported on the National Institutes of Health (NIH) as highlighted in this link https://www.nih.gov/news-events/news-releases/stem-cell-transplants-may-induce-long-term-remission-multiple-sclerosis
About Shiva Gopal Vasishta
Dr. Shiva Gopal Vasishta is a new Jersey-based neurologist. He works at the Kennedy University Hospital. Here, Vasishta is part of a team of 34 doctors that specializes in Neurology. The doctor has broad experience in treating multiple sclerosis, sleep disorder, stroke, dementia, and headaches. Dr. Shiva Gopal Vasishta pursued his medical degree from the Government Medical College.
He successfully completed his residency in Neurology at Tufts Medical Center and Boston University Medical Center. Shiva is certified by the American Board of Psychiatry and Neurology and holds an NJ State Medical License. Dr. Shiva Gopal Vasishta practices psychiatry at the Eastern Neurodiagnostic Associates. Notably, Dr. Shiva Gopal Vasishta has been accepting different insurance plans, including Horizon Blue Cross Blue Shield, Medicare and Aetna.